Rheumatology 2007;46:1852–1857 doi:10.1093/rheumatology/kem240
Advance Access publication 12November 2007
Effect of annual intramuscular vitamin D on fracture risk in
elderly men and women—a population-based, randomized,
double-blind, placebo-controlled trial
H. Smith, F. Anderson1, H. Raphael, P. Maslin, S. Crozier2 and C. Cooper2
Objectives.Lowtraumafracturesinolderpeopleincurenormousphysical,socialandeconomiccosts.Previousresearchindicatesthatan
annualintramuscularinjectionofvitaminDmayreducefractureratesinthisgroup.Thisstrategyrequiresvalidationinapopulationsetting.
Methods. Randomized, double-blind, placebo-controlled trial of 300000 IU intramuscular (i.m.) vitamin D (ergocalciferol) injection or
2
matchingplaceboeveryautumnover3years.9440people(4354menand5086women)aged75yrsandoverwererecruitedfromgeneral
practice registers in Wessex, England.Primary outcome measure was all non-vertebral fracture. Secondary outcomes were hip and wrist
fractures,andallfalls.
Results.585subjectshadincidentnon-spinefractures(hip110,wrist116,ankle37).Hazardratios(HRs)forfractureinthevitaminDgroup
were:1.09[95%confidenceinterval(CI)0.93–1.28,P¼0.29]foranyfirstfracture,1.49(95%CI1.02–2.18,P¼0.04)forhipand1.22(95%
CI0.85–1.76,P¼0.28)forwrist.Therewasnoeffectonfalls:HR0.98(0.93–1.04).Noprotectiveeffectwasobservedinanysubgroupwhen
thecohortwasstratifiedbysex,age,previousfractureormobility.
Conclusions.Anannuali.m.injectionof300000IUvitaminD isnoteffectiveinpreventingnon-vertebralfracturesamongelderlymenand
2
womenresidentinthegeneralpopulation.
KEYWORDS: Fracture,Epidemiology,Osteoporosis,VitaminD,Prevention.
Introduction Methods
Osteoporotic fractures are a major public health problem, and Study design
their incidence is projected to increase steeply worldwide [1].
The study was a randomized, double-blind, placebo-controlled
The social and economic costs associated with osteoporotic
trial of 300000 IU ergocalciferol (Evans Medical Ltd/Celltech
fractures are very great [2], and reducing this burden is widely
Ltd, UK) by i.m. injection in men and women aged over 75 yrs
seen as a health care policy imperative. Vitamin D deficiency is
recruited from the practice registers of 111 general practices
commoninelderlypeople,especiallythosewithhipfracture,and
includedintheWessexPrimaryCareResearchNetwork(WReN)
Vitamin D supplementation, ifeffective, might providea feasible
in central Southern England [8]. Previous studies have demon-
and relatively cost-effective primary preventive measure against
stratedthattheage,genderandsocioeconomicprofileofpractices
fractureamongoldermenandwomen.Previousstudiesofvitamin
enrolled within this network are representative of England and
D supplementation among older people in western populations
Walesasawhole[9].InstitutionalReviewBoardapprovalforthe
haveproducedinconsistentresults.Whencombinedwithcalcium
study was obtained from the South West Multi-centre Research
in daily oral formulations, the intervention has been shown to
Ethics Committee (MREC/98/6/51).
reduce the incidence of osteoporotic fractures among elderly
nursinghomeresidents[3];whenadministeredorallyandwithout
Recruitment and randomization
calcium supplementation, fracture prevention has been more
difficult to demonstrate [4–6]. Vitamin D may also be adminis- The influenza immunization programme in England and Wales
tered by intramuscular (i.m.) injection, and a single non- offersimmunization annually toall adultsover65yrs ofage; we
randomized trial of men and women aged 85 yrs and over utilizedthisframeworktoselectourstudysampleontheprinciple
administeredanannuali.m.injectionofergocalciferolvitaminD that, were the intervention to prove effective, this would provide
2
(150000–300000 IU) resulted in a significant reduction in the a cost-effective way of implementing the intervention as a public
incidenceofallfracturesovera5-yrperiod,whencomparedwith health measure. Men and women aged over 75 yrs who did not
acontrolseries[7].Wereporttheresultsofarandomized,double- meet any of the study exclusion criteria (current cancer or
blind, placebo-controlled trial of 300000 IU i.m. ergocalciferol any history of treated osteoporosis, bilateral total hip replace-
injection ormatching placebo onfracture rates among9440men ment, renal failure, renal stones, hypercalcaemia or sarcoidosis)
and women aged 75 yrs and over, resident in the general were identified from the age–sex registers of participating
practices.Aninformation leafletaboutthestudywithacovering
population.
letterfromtheirpracticewassenttopotentialparticipants.Those
interested in participating were asked to return a form giving
details of any vitamin D supplementation they took already.
People taking (cid:1)400 IU or more daily were excluded from
Department of Primary Care, Division of Community-based Clinical Sciences, the study. The remainder were invited to an appointment with
1GeriatricMedicineGroupand2MRCEpidemiologyResourceCentre,Universityof the practice nurse, who confirmed their understanding of
Southampton,SouthamptonGeneralHospital,SouthamptonSO166YD,UK. the study, checked for exclusion criteria not recorded in existing
Submitted10April2007;revisedversionaccepted8August2007. medical records and obtained written informed consent.
A questionnaire ascertained details of previous fractures, current
Correspondence to: C. Cooper, Professor of Rheumatology and Director,
MRC Epidemiology Resource Centre, Southampton General Hospital, mobility and accommodation. The numbers of subjects invited
SouthamptonSO166YD,UK.E-mail:cc@mrc.soton.ac.uk andrandomized are shownin Fig. 1.
1852
(cid:1)TheAuthor2007.PublishedbyOxfordUniversityPressonbehalfoftheBritishSocietyforRheumatology.Allrightsreserved.ForPermissions,pleaseemail:journals.permissions@oxfordjournals.org
Downloaded
from
http://rheumatology.oxfordjournals.org/
at
New
York
University
on
May
20,
2015
Intramuscularvitamin D andfracture 1853
Eligible (n = 13487)
Randomized (n = 9440)
Allocated to placebo (n = 4713) Allocated to vitamin D (n = 4727)
Received placebo (n = 4713) Received vitamin D (n = 4727)
6 months: 6 months:
Did not return questionnaire (n = 168, 3.6%) Did not return questionnaire (n = 179, 3.8%)
Analysed (n = 4545) Analysed (n = 4548)
Fractured (n = 55) Fractured (n = 68)
12 months: 12 months:
Did not return questionnaire (n = 375, 8.0%) Did not return questionnaire (n = 377, 8.0%)
Analysed (n = 4115) Analysed (n = 4103)
Fractured (n = 45) Fractured (n = 54)
Did not receive i.m. injection (n = 28) Did not receive vitamin D (n = 28)
18 months: 18 months:
Did not return questionnaire (n = 296, 6.3%) Did not return questionnaire (n = 282, 6.0%)
Analysed (n = 3774) Analysed (n = 3767)
Fracture (n = 59) Fractured (n = 61)
24 months: 24 months:
Did not return questionnaire (n = 361, 7.7%) Did not return questionnaire (n = 306, 6.5%)
Analysed (n = 3354) Analysed (n = 3400)
Fractured (n = 49) Fractured (n = 46)
Did not receive i.m. injection (n = 2) Did not receive vitamin D (n = 0)
30 months: 30 months:
Did not return questionnaire (n = 306, 6.5%) Did not return questionnaire (n = 308, 6.5%)
Analysed (n = 2434) Analysed (n = 2467)
Fractured (n = 36) Fractured (n = 36)
36 months: 36 months:
Did not return questionnaire (n = 132, 2.8%) Did not return questionnaire (n = 127, 2.7%)
Analysed (n = 2266) Analysed (n = 2304)
Fractured (n = 35) Fractured (n = 41)
FIG.1. FlowdiagramforsubjectsintheWessexFracturePreventionTrial.
Intervention on falls, current mobility and residential status was obtained at
annualreview(12,24and36months)bythepracticenurseandon
Subjects were randomized at an individual level to either the
incidentfracturesbypostalquestionnaireat6,12,18,24,30and
intervention or control group. Randomization was balanced in
36 months. Fracture history on the questionnaire was corrobo-
eachofthe111practicesitesbyrandomizingwithinblocksateach
rated at the annual visits to the practice nurse,as well as against
practice. Each participating practice was sent mixed boxes hospital and general practice records. Non-responders to the
containing previously randomized, numbered ampoules of either ‘interval’questionnairesweresentonereminderafter4weeksand
vitamin D or placebo, which were identical in visual appearance were contacted by telephone after a further 2 weeks if necessary.
and consistency. As each subject consented to participate in the Participants continued their usual drug treatment and any new
trial, they were allocated consecutive ampoules. The number of drugs that were advised during routine care. Recruitment
theampoulewasthenlinkedtothepatient’snameandphonedto commenced in autumn 1998, and follow-up was completed in
a central location. This study number remained with the subject autumn 2002.
forthedurationofthetrial.Thetrialinjectionwasthengiveni.m.
intothebuttockorleg.Packingandlabellingwerecarriedoutby
Outcome ascertainment
an external contractor; allocation was concealed from investiga-
tors, practice nurses and subjects. After completion of the Theprincipaloutcomeofthetrialwasallnon-vertebralfractures.
recruitment phase, all study documentation was checked at each Secondary outcomes were fractures of the hip or wrist, and the
practice by the trial manager (HMR) and, together with any frequency of falls. Study events were self-reported by subjects at
unusedampoules,returnedtothecentralstudyoffice. 6-monthly intervals using the fracture questionnaire validated in
the European Prospective Osteoporosis Study [10]. This inquires
about fractures over the intervening 6 months, and is accom-
Follow-up
panied by a mannequin on which the fracture site is indicated.
Activeorplaceboinjectionswereadministeredatannualintervals Any fracture reported by study participants was confirmed from
andconcealedinthesamewayasthefirstinjection.Information hospital and practice records. Separately, practices notified any
Downloaded
from
http://rheumatology.oxfordjournals.org/
at
New
York
University
on
May
20,
2015
1854 H. Smith etal.
TABLE1. Characteristicsof4354menand5086womenaged75yrsandover,randomizedtotreatmentwithvitaminDorplacebo
Men Women All
Baseline
characteristic Placebo VitaminD Placebo VitD Placebo VitaminD
No. 2195 2159 2518 2568 4713 4727
Medianage(IQR)a 79.1 79.0 79.2 79.3 79.1 79.1
(76.9–82.4) (76.8–82.1) (77.0–82.8) (77.1–83.1) (76.9–82.6) (76.9–82.7)
Previousfractures
Anynon-vert.(%) 36.0 34.2 40.8 39.8 38.5 37.2
Hiporfemur(%) 1.9 2.1 3.7 3.2 2.9 2.7
Wristb(%) 8.9 7.0 18.5 18.1 14.0 13.0
Accommodation
Own/spouse(%) 91.2 91.4 84.3 83.9 87.5 87.3
Withfamily(%) 3.1 3.0 4.4 4.7 3.8 4.0
Warden(%) 4.2 4.6 9.3 9.2 6.9 7.1
Residential(%) 1.0 0.5 1.7 1.7 1.4 1.2
Other(%) 0.6 0.4 0.3 0.6 0.4 0.5
aIQR,interquartilerange.
bOrradius,ulnaorColles’fracture.
reported fracture in their patients directly to the trial office. TABLE 2. Incidence of first fractures and age-adjusted HRs (Cox regression) of
treatmentwithvitaminDcomparedwithtreatmentwithplacebo
A fracture was treated as confirmed if it met two of the three
criteria:reportbystudysubject;reportbypractice;andconfirma-
Fractures Placebo VitaminD HRa(95%CI) P-value
tion from hospital records. Fracture sites were coded using the
fracture classification adopted by the International Classification All
ofDiseases, 9thRevision. Ahistoryoffalls duringthe preceding No. 4713 4727
Anynon-vertebral 279 306 1.09(0.93–1.28) 0.29
6-monthperiod wasalso obtained from the questionnaire.
Hiporfemur 44 66 1.49(1.02–2.18) 0.04
Aninterviewer-administered questionnairewasperformedina Wristb 52 64 1.22(0.85–1.76) 0.28
randomlyselectedsubsetof200trialparticipants,whichinquired Hip,femurorwristb 92 129 1.40(1.07–1.82) 0.02
about previous fracture history, dietary calcium intake, physical Falls 2577 2544 0.98(0.93–1.04) 0.50
activity, cigarette smoking, alcohol consumption, medical and Men
No. 2195 2159
drughistory and reproductive variables in women.
Anynon-vertebral 85 68 0.81(0.59–1.11) 0.20
Hiporfemur 18 18 1.02(0.53–1.97) 0.94
Statistical analyses Wristb 8 4 0.50(0.15–1.66) 0.26
Hip,femurorwristb 26 22 0.86(0.49–1.52) 0.61
An intention-to-treat analysis was performed, which included all Falls 1145 1092 0.97(0.89–1.05) 0.46
participants randomized. We compared crude incidence rates for Women
fracture amongst those treated with vitamin D and placebo; we No. 2518 2568
Anynon-vertebral 194 238 1.21(1.00–1.47) 0.05 thenestimatedhazardratios(HRs)usingCoxregressioninStata
Hiporfemur 26 48 1.80(1.12–2.90) 0.02
7.0,afteradjustmentforage.Datawerecensoredatthetime-point Wristb 44 60 1.34(0.91–1.98) 0.14
at which a fracture was reported, the most recent questionnaire Hip,femurorwristb 66 107 1.59(1.17–2.16) 0.003
Falls 1432 1452 0.99(0.92–1.06) 0.78
wascompleted,oratthecompletionofstudyfollow-up.Subjects
who did not return a questionnaire at one time-point, but then
aHRsadjustedforage.
returned a later questionnaire continued to contribute to earlier bOrradius,ulnaorColles.
follow-uponly.Thestudyhad80%powertodetectadifferencein
fracturerateof30%(3.3%orlower,fromabaselineof4.7%[11])
atthe5%significancelevel,with5000patientsineacharm.This
allowed for a20% dropoutrate. Results
The 111 participating general practices invited 13 487 potential
Calcium biochemistry
participants over a 3-yr period. Of these, 9440 people (4354 men
In a pilot of 43 subjects eligible to enter the trial (30 treated, and5086women)werewillingtoparticipateandwereconfirmed
13placebo),wecollectedbloodsamplesformeasurementofserum to meet the study entry criteria. 3188 subjects were recruited
25-hydroxyvitamin D (25-OHD), (1,25)-dihydroxyvitamin D duringthefirstyearofthestudy,4692duringthesecondyearand
(1,25-DHD) and plasma parathyroid hormone (PTH) concentra- 1560 during the third year. The remaining 4047 were ineligible
tions.Sampleswerecollectedatbaselinethenat1,4,8,12,13and (n¼2185;54%)ordeclinedtoparticipate(n¼1862;46%).Thus,
16 months, covering two treatment cycles. Blood was taken of the 11302 people who were eligible, 9440 (83.5%) were
without haemostasis into glass tubes containing coagulant and willing to participate. Table 1 shows the baseline characteristics
proteaseinhibitor,andthenseparatedinarefrigeratedcentrifuge. of the subjects randomized. Their median age was 79.1 yrs
Serum was transferred to cryotubes and frozen at (cid:2)708C until (IQR76.9–82.6yrs);therewerenoappreciabledifferencesbetween
analysed in one batch at the end of the collection period. the groups in age, previous history of fracture, prevalence and
1,25-DHD was assayed by RIA after immunoextraction (IDS frequencyoffallsinthelast6monthsorresidentialstatus.Thirty-
Limited, Tyne & Wear, UK), 25-OHD by RIA (Nicholls eight per cent of the men and women had sustained a previous
Diagnostics, CA, USA). PTH was measured on a DPC clinical fracture (wrist14%; ankle 7.4%;hip2.8%).
Immulyte analyser. Biochemical studies were performed in a 2:1 Table2showsthenumberofsubjectswithanincidentfracture
ratio of treated:placebo subjects to enhance precision in the in the placebo and treated groups. Eighty-five men and 194
treated group; the subjects comprised consecutive eligible atten- women in the placebo group sustained an incident fracture over
dees at a single practice. Paired and non-paired t-tests (as the3-yrfollow-upperiod.Thesecontrastedwith68menand238
applicable) and ANOVA were used to assess differences between womeninthevitaminD-treatedgroup.Therewasnoevidencefor
groupsofdifferenttime-pointsandchangesfrombaselinevalues. a protective effect of vitamin D against fracture at any site: all
Downloaded
from
http://rheumatology.oxfordjournals.org/
at
New
York
University
on
May
20,
2015
10
8
6
4
2
0
0 6 12 18 24 30 36 0 6 12 18 24 30 36
Months Months
0 6 12 18 24 30 36 0 6 12 18 24 30 36
Months Months
fractures[HR1.09;95%confidenceinterval(CI)0.93–1.28],wrist (P¼0.03). Among the 200 trial participants completing the
(HR1.22;95%CI0.85–1.76),ankle(HR1.63;95%CI0.84–3.17). moredetailedinterviewer-administered questionnaire,22subjects
There was a small, but statistically significant (P¼0.04) excess (11%) had sustained a previous hip or wrist fracture; 48 (24%)
risk of hip fracture associated with allocation to treatment with reported<30minweight-bearingactivityeachday;74(37%)had
vitaminD(HR1.49;95%CI1.02–2.18).Whenthegenderswere ever smoked; and only four consumed greater than 20 units of
analysed separately, the tendency for an increase in fracture risk alcoholeachweek.Themeandietarycalciumintakeofthese200
was particularly observed among women, in whom there was a subjects was 625mg daily (S.D.231).
59% increase in hazard at the proximal femur or distal forearm In the biochemistry study, measurements were obtained at
among those treated with vitamin D compared with placebo baseline,andat1,4,8,12,13and16monthsoffollow-up.Among
(P¼0.003).TherewasnosignificanteffectofvitaminDtreatment the 43 trial participants included, mean plasma 25-OHD
onthe frequency of falls (HR 0.98;95%CI 0.93–1.04). concentration at baseline was 56.5ng/ml (S.D.23.7); PTH con-
Figure2showsthecumulativeprobabilityoffractureatvarious centration 4.83pmol/l (IQR 3.92–5.63); and 1,25-DHD concen-
skeletalsitesaccordingtotreatmentgroup.Itshowsstepsbetween tration 74.3pmol/l (S.D. 27.5). Increases from baseline were
6-monthly assessments, as unknown fracture time-points were observed in 25-OHD and 1,25-DHD concentrations among
interpolatedinthismanner.Forallnon-spinefractures,therewas those subjects receiving active treatment, but not in those on
almostnodivergenceinthecumulativeincidencepatternbetween placebo. For 25-OHD, the actively treated group showed a 21%
the vitamin D and placebo-treated patients over the 3 yrs of the increase at 4 months, but this was not statistically significant
study. Whenthe analyseswere confined to fractures atthe wrist, (P¼0.15). There was a more pronounced increase in 1,25-DHD
hiporbothofthesesites,fractureincidencetendedtobehigherin concentrationoverthisperiod(35.7%)andthisattainedstatistical
the vitamin D-treated arm when compared with those subjects significance (P¼0.02). At this time-point, the difference
using placebo. However, these differences were not statistically between absolute 1,25-DHD concentrations (but not 25-OHD
significant forthe wrist (HR¼1.22,95%CI 0.85–1.76). concentrations) among actively treated and placebo subjects
Therewerenostatisticallysignificantinteractionsbetweenage, was also statistically significant (P<0.002). These changes in
previous fracture history or functional status and the effects of vitamin D status were accompanied by only modest (17%)
vitamin D treatment on fracture risk; these tests of interaction suppression of PTH in the treated subjects at this time-point,
were exploratory and not pre-planned. There was, however, a a level which did not attain statistical significance. By the eighth
significantinteractionbetweengenderandtreatmentgrouponthe month after injection, these changes had drifted towards basal
risk of any non-spine fracture such that a detrimental effect of values, although the significantly higher 1,25-DHD levels in
vitamin D was seen amongst women, but not among men the active group persisted (P¼0.04). Observations during the
derutcarf
%
Cumulative probability of fracture at any non-vertebral site
2
1.5
Vitamin D
Placebo 1
0.5
0
derutcarf
%
Cumulative probability of fracture at hip or femur
Vitamin D
Placebo
2
1.5
1
0.5
0
derutcarf
%
Cumulative probability of fracture at wrist, radius or ulna
4
3
Vitamin D 2
Placebo
1
0
derutcarf
%
Intramuscularvitamin D andfracture 1855
Cumulative probability of fracture at hip, femur,
wrist, radius or ulna
Vitamin D
Placebo
FIG.2. Cumulativeprobabilityoffractureatvariousskeletalsites,accordingtotreatmentwithvitaminDorplacebo.
Downloaded
from
http://rheumatology.oxfordjournals.org/
at
New
York
University
on
May
20,
2015
1856 H. Smith etal.
second year of follow-up (after a second vitamin D or placebo the practices in the Wessex Primary Care Network was
injectionduringthefall)broadlyresembledthoseinthefirstyear representative of England and Wales, our study participants
of the study. were likely tohave hadhigher functionalcapacitythanthe older
populationfromwhichtheyweredrawn;theyweremorelikelyto
liveintheirownhomes,andhadaslightlylowerthanexpectedhip
Discussion
fracture rate. Finally, information on falls was collected retro-
This large, pragmatic, population-based, randomized, double- spectively by practice nurse interview or a postal questionnaire
blind,placebo-controlledtrialfoundthatanannuali.m.injection enquiringaboutfallsoverthepast6months.Althoughfallswere
of 300000 IU vitamin D did not reduce fracture risk when only a secondary outcome measure of the trial, it has been
comparedwithplacebo.Thisisthelargesttrialtodateaddressing established that prospective collection of falls data at frequent
the primary prevention of osteoporotic fractures in older people intervals is more reliable than retrospective assessment over long
andthelargesttrialofi.m.vitaminD.Thetrialinvolvedover9000 periods [16].
menandwomenaged75yrsandover;itwasadequatelypowered VitaminDinsufficiencyiswidespreadintheelderlypopulation
todetecta30%differenceinfractureratebetweentreatmentand of northernEuropeand theUSA[17–19]. Supplementationis an
placebo arms. The baseline rate of all non-osteoporotic fractures effectivewayofpreventingthis.Adailyoraldoseof400–800IU
wasclosetothatexpectedusingroutinelyderivedepidemiological has been shown to elevate serum 25-OHD levels, reduce serum
dataforEnglandandWales[11].Therewere,however,fewerhip PTH and suppress markers of bone turnover in vulnerable older
fracturesthananticipated,reflectingtherelativelyhealthyelderly people[5,6,20]butitscostutilityinfracturepreventionremains
populationwhochosetotakepartinthestudy.Thegroupswere uncertain.GivingperiodicvitaminDsupplementationbythei.m.
wellbalancedatentrytothetrial,andindividualswhopreviously route, while somewhat invasive, has advantages over daily oral
usedsupplementscontaining400IUvitaminDormoredailywere supplementsincost-effectivenessandcompliance.However,fewer
excluded from entry. The method of ascertaining non-spine data are available on the effect of i.m. dosing on circulating
fractureshasbeenwellvalidatedpreviously,andthevastmajority vitamin D metabolites. One study comparing i.m. with i.v. and
of these could be corroborated from a second source (hospital oralvitaminDshowedadelayedriseinserum25-OHDlevelswith
notesorradiographic records). the i.m. route. The study also showed that in a rat model about
This was a large, pragmatically designed, randomized con- half of the vitamin D administered by i.m. injection remained
trolled trial. As a consequence, the principal issue addressed was unaltered in situ [21], providing an additional reason why this
thecapacityofapublichealthprogrammeofannuali.m.vitamin particularmodeofdeliveryprovedineffective.Afurtherpossible
Dinjectionsintheelderly,toreducefractureincidence.Thishad problem is the potential absorption of vitamin D on plastic
2
already been suggested by a smaller, non-randomized study. The syringes, although quality assurance on the ampoules used was
major deficiency of the study was the relative paucity of undertakenat a nationalreference laboratory.
explanatory measures such as assessment of vitamin D status in The effect of vitamin D supplementation on the risk of non-
theenrolledsubjects,aswellasotherdeterminantsoffracturerisk vertebral fracture is unclear despite several large, well-designed
suchasdietarycalciumintake,smoking,alcoholconsumptionand placebo-controlled trials. Two studies of daily oral supplementa-
physical activity. We were able to recruit a small sample of tion using vitamin D combined with calcium demonstrated
participants in whom circulating levels of 25-OHD, 1,25-DHD significant decreases in non-vertebral fractures among 3270
and PTH were able to be evaluated over a protracted period female nursing home residents in France [3] and in 445relatively
within the study. Although too small to allow detailed inference, healthy men and women in the USA [22]. In the first of these,
this subset clearly demonstrated that our subjects were relatively supplementation appearedto have itsprincipal effecton fracture
vitaminDreplete,withonlyaround25%fallingintotherangeof incidence within 18–24 months of commencing therapy. In the
modestorseveredeficiency(<30ng/ml).Withhindsight,itwould second,theplacebofractureratewasamongthehighestrecorded
have been preferable to increase the size of this biochemical in controlled trials of osteoporosis interventions (around 22%,
subset, but the available data suggest that this intervention was comparedwith12%inotherstudiesofanti-resorptivetreatment).
ineffective in reducing fractures in a relatively vitamin D replete In contrast, studies of daily oral vitamin D without calcium
population. Additionally, the 25-OHD assays that were utilized supplementationhavereportedlessornobenefitonfracturerates.
may have been less reliable in the estimation of vitamin D . Examples include a study of 2578 elderly independent men and
2
We did obtain more detailed risk factor information in 200 womenfromHollandrandomizedto400IUvitaminD orplacebo
3
participants that were in accord with the biochemical subset, in [5], or one of 1100 residents of Norwegian nursing homes
revealingcalciumintakesaroundthevaluespreviouslyreportedin randomized to 5ml cod liver oil or placebo [6]. Trials using
the healthy UK elderly, and certainly well above those found intermittentdosingofvitaminDhavebeenmorelikelytoshowa
amongpreviouslypublishedstudiesreportingabenefitofcalcium reductioninfracturerisk.Atrialof100000IUoralcholecalciferol
and vitamin D supplementation. These deficiencies limited our or placebo every 4 months in 2686 community-dwelling British
ability to perform subgroup analyses adjusting for the effects of menandwomenaged(cid:1)65yrsfoundsignificantreductionsinthe
calcium intake, vitamin D status or PTH. A third caveat is that relative risk of any fracture (HR 0.78; 95% CI 0.61–0.99), or
our intervention was vitamin D , and data published after the fracture at the hip, wrist, forearm or spine (HR 0.67; 95% CI
2
inception of this trial confirm that vitamin D has an attenuated 0.48–0.93)[4].Thestudythatinspiredthiscurrenttrialutilizedan
2
effect when compared with vitamin D [12–15]. The relative annual i.m. injection of 150000–300000 IU ergocalciferol in 479
3
potency of the plant sterol ergocalciferol (vitamin D ) and the Finnishmenandwomenaged>85yrswhowerelivingintheirown
2
animalform,cholecalciferol(vitaminD )isdisputed;comparison home and 320 subjects aged 75–84 yrs living in a home for aged
3
of D and D potency in humans has given conflicting results people. Although treatment allocation was inadequately rando-
2 3
[12, 13]. The most recent study contrasting the effectiveness of mized by current standards (using alternate allocation without
vitaminD withthatofvitaminD suggestedthatbothcalciferols blinding),thegroupofsubjectsadministeredi.m.vitaminDhada
2 3
produced similar rises in serum 25-OHD concentration over significantly (P¼0.03) lower rate of all fractures. This was
3 days, but that levels declined much more rapidly in subjects particularly marked (P¼0.02) for fractures of the upper limb,
treatedwithD [14].Weoptedtousetheidenticalformulationof butwasnotapparentforlowerlimbsites[7].Thepresentstudywas
2
ergocalciferol that was utilized in the previous Finnish study [7]. considerably larger, subjects were randomized to treatment or
However, our dosing frequency was annual and the pharmaco- placebo and outcomes were assessed in a blind fashion using
kinetics of i.m. vitamin D might differ if administered more validated measures. Our results clearly do not support those of
frequently.Althoughtheage,genderandsocioeconomicprofileof the Finnish study and suggest that an annual i.m. injection of
Downloaded
from
http://rheumatology.oxfordjournals.org/
at
New
York
University
on
May
20,
2015
Intramuscularvitamin D andfracture 1857
vitaminDdoesnotresultinameasurablereductionintheriskof References
non-vertebralfractures,perhapsduetoinsufficientsuppressionof
PTH. Two recent studies of intermittent oral vitamin D admin- 1 Cooper C, Campion G, Melton LJ III. Hip fractures in the elderly: a world-wide
projection.OsteoporosisInt1992;2:285–9.
istration,incontrast,havefailedtorevealareductioninfracture
2 DolanP,TorgersonDJ.ThecostoftreatingosteoporoticfracturesintheUnited
risk [23, 24], Finally, the recently published Medical Research Kingdomfemalepopulation.OsteoporosisInt1998;8:611–7.
Council Randomized Evaluation of Calcium or Vitamin D 3 Chapuy MC, Arlot ME, Duboeuf F et al. Vitamin D3 and calcium to prevent hip
(RECORD) Trial evaluated daily oral calcium, vitamin D, fracturesintheelderlywomen.NewEnglJMed1992;327:1637–42.
4 Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3
both interventions combined, and double placebo, in 5292 men
(cholecalciferol) supplementation on fractures and mortality in men and women
and women aged 70 yrs and over, who had sustained a low living in the community: randomised double blind controlled trial. Br Med J
traumafracture[25].Inaccordancewiththeresultsofourstudy, 2003;326:469.
vitamin D whether alone or in combination with calcium 5 Lips P, Graafmans WC, Ooms ME, Bezemer PD, Bouter LM. Vitamin D
supplementationandfractureincidenceinelderlypersons.Arandomized,placebo-
supplementation was ineffective in reducing the incidence of
controlledclinicaltrial.AnnInternMed1996;124:400–6.
fracture. These complex findings have been thoroughly reviewed 6 Meyer HE, Smedshaug GB, Kvaavik E, Falch JA, Tverdal A, Pedersen JI. Can
with the recent publication of the calcium and vitamin D vitaminDsupplementationreducetheriskoffractureintheelderly?Arandomized
controlledtrial.JBoneMinerRes2002;17:709–15.
component of the Women’s Health Initiative [26]. Our data are
7 HeikinheimoRJ,InkovaaraJA,HarjuEJetal.AnnualinjectionofvitaminDand
also in accordance with recent randomized controlled trials fracturesofagedbones.CalcifiedTissueInt1992;51:105–10.
of calcium supplementation in elderly women [27, 28], in which 8 vanWeelC,SmithH,BeasleyJW.Familypracticeresearchnetworks.Experiences
significantreductionsin fractureriskwere notobserved.Aswith from3countries.JFamPractice2000;49:938–43.
9 Bradley F, Morgan S, Smith H, Mant D. Preventive care for patients following
one of these studies, we also found a statistically significant
myocardial infarction. The Wessex Research Network (WReN). Fam Pract
excessriskofhipfractureintheinterventiongroup[27];wearenot 1997;14:220–6.
awareofanybiologicallyplausiblereasonwhycalciumorvitamin 10 IsmailAA,O’NeillTW,CockerillWetal.andtheEPOSStudyGroup.Validityofself-
Dsupplementationshouldincreasehipfractureriskandweconcur report of fractures: results from a prospective study in men and women across
Europe. EPOS Study Group. European Prospective Osteoporosis Study Group.
withtheauthorsofthatreportthattheseobservationsarelikeliest
OsteoporosisInt2000;11:248–54.
due to chance. A remote possibility is that if a small number of 11 vanStaaTP,DennisonEM,LeufkensHG,CooperC.Epidemiologyoffracturesin
participantshadvitaminDdeficiencyandosteomalacia,treatment EnglandandWales.Bone2001;29:517–22.
with vitamin D might have led to a rapid improvement in 12 RapuriPB,GallagherJC,HaynatzkiG.EffectofvitaminsD2andD3supplementuse
onserum25OHDconcentrationinelderlywomeninsummerandwinter.Calcified
myopathy,butthemineralizationdeficitmighthavepersistedfor
TissueInt2004;74:150–6.
several months. In this situation, improved mobility might have 13 TrangHM,ColeDE,RubinLA,PierratosA,SiuS,ViethR.EvidencethatvitaminD3
been associated with an increased risk of hip fracture. The latest increasesserum25-hydroxyvitaminDmoreefficientlythandoesvitaminD2.AmJ
Cochrane Review addressing this issue [29], and a recent meta- ClinNutr1998;68:854–8.
analysis [30] all concur that vitamin D alone is ineffective in
14 ArmasLA,HollisBW,HeaneyRP.VitaminD2ismuchlesseffectivethanvitaminD3
inhumans.JClinEndocrinolMetab2004;89:5387–91.
preventing fractures among older people, but that combined 15 HoughtonLA,ViethR.Thecaseagainstergocalciferol(vitaminD2)asavitamin
calcium and vitamin D supplementation may decrease the supplement.AmJClinNutr2006;84:694–7.
incidence of hip and other non-vertebral fractures, especially in 16 Ganz DA, Higashi T, Rubenstein LZ. Monitoring falls in cohort studies of
community-dwelling older people: effect of the recall interval. J Am Geriatr Soc
carehomeresidents.
2005;53:2190–4.
In conclusion, we have performed a large, pragmatic, ran- 17 ChapuyMC,PreziosiP,MaamerMetal.PrevalenceofvitaminDinsufficiencyinan
domized,controlledtrialcomparingtheanti-fractureeffectiveness adultnormalpopulation.OsteoporosisInt1997;7:439–43.
of a single i.m. injection of 300000 IU vitamin D annually 18 LeBoffMS,KohlmeierL,HurwitzS,FranklinJ,WrightJ,GlowackiJ.OccultvitaminD
2 deficiency in postmenopausal US women with acute hip fracture. JAMA
with placebo over a 3-yr period. Although acceptable and safe,
1999;281:1505–11.
this intervention was not effective in reducing the incidence 19 Gloth FM III, Gundberg CM, Hollis BW, Haddad JG, Jr, Tobin JD. Vitamin D
of fractures among men and women aged over 75 yrs resident deficiencyinhomeboundelderlypersons.JAMA1995;274:1683–6.
in the generalpopulation. 20 GennariC.CalciumandvitaminDnutritionandbonediseaseoftheelderly.Public
HealthNutr2001;4:547–59.
21 WhyteMP,HaddadJGJr,WaltersDD,StampTC.VitaminDbioavailability:serum
Rheumatology key messages 25-hydroxyvitaminDlevelsinmanafteroral,subcutaneous,i.m.,andintravenous
vitaminDadministration.JClinEndocrMetab1979;48:906–11.
(cid:3) The effectiveness of annual vitamin D injections in preventing 22 Dawson-HughesB,HarrisSS,KrallEA,DallalGE.EffectofcalciumandvitaminD
supplementation on bone density in men and women 65 years of age or older.
osteoporoticfracturesisunknown.
NewEnglJMed1997;337:670–6.
(cid:3) The large, randomized, controlled trial demonstrates that i.m.
23 Law M, Withers H, Morris J, Anderson F. Vitamin D supplementation and the
vitamin D injection administered on an annual basis does not preventionoffracturesandfalls:resultsofarandomisedtrialinelderlypeoplein
preventosteoporoticfracture. residentialaccommodation.AgeAgeing2006;35:482–6.
24 JohansenA,LyonsRA,StoneMetal.Preventingfracturesamongolderpeopleliving
ininstitutionalcare:arandomiseddoubleblindplacebocontrolledtrialofvitaminD
Acknowledgements supplementation.AgeAgeing2006;35(Suppl3):i41.
25 TheRECORDTrialGroup.OralvitaminD3andcalciumforsecondaryprevention
We thank the General Practitioners and patients who partici- of low trauma fractures in elderly people (randomised evaluation of calcium
pated.JulieSmithandTanyaHumphreysprovidedadministrative or vitamin D, RECORD): a randomised placebo-controlled trial. Lancet
support;VanessaCoxmanagedthedata.Thereportwasprepared 2005;365:1621–8.
26 FinkelsteinJS.CalciumplusvitaminDforpostmenopausalwomen–boneappe´tit?
by Gill Strange. We are also grateful to the external Advisory
NewEnglJMed2006;354:750–2.
Group: Dr S Drew, Dr S Clayton, Mr D Matthews, Mrs B 27 ReidIR,MasonB,HorneAetal.Randomisedcontrolledtrialofcalciuminhealthy
Hughes andMrsSue O’Regan. olderwomen.MJMed2006;119:777–85.
28 PrinceRL,DevineA,DhaliwalSS,DickIM.Effectsofcalciumsupplementationon
Funding: The study was supported by the Medical Research clinical fracture and bone structure: results of a 5-year double blind placebo
Council of Great Britain, the South West NHS Research and controlledtrialinelderlywomen.ArchInternMed2006;166:869–75.
29 Avenell A, Gillespie WJ, Gillespie LD, O’Connell DL. Vitamin D and vitamin D
DevelopmentDirectorate,theNationalOsteoporosisSocietyand
analoguesforpreventingfracturesassociatedwithinvolutionalandpost-menopausal
Celltech UK plc. osteoporosis.CochraneDBSystRev2005;3:CD000227.
30 BoonenS,LipsP,BouillonR,Bischoff-FerrariHA,VanderschuerenD,HaentjensP.
Disclosure Statement: F. A. has received honoraries from Shire Need for additional calcium to reduce the risk of hip fracture with vitamin D
Pharmaceuticals and Prostrakan ltd for lecturing at educational supplementation: evidence from a comparative meta-analysis of randomised
meetings.Allotherauthorshavedeclarednoconflictsofinterest. controlledtrials.JClinEndocrinolMetab2007;92:1415–23.
Downloaded
from
http://rheumatology.oxfordjournals.org/
at
New
York
University
on
May
20,
2015
